Experimental Treatments for Terminal Conditions and Life-threatening Rare Diseases
S Died in Health Policy
Email me when SB 1552 moves
Committee action, floor votes, amendments and hearings. Free, no card, no password.
Already have an account? Track SB 1552. By continuing you agree to the Terms and Privacy Policy.
Summary
The Promising Pathways Act lets licensed physicians prescribe, and eligible hospitals administer, experimental drugs that have passed Phase 1 but are not yet FDA‑approved, to patients with terminal illnesses or life‑threatening rare diseases. It requires informed consent, IRB oversight, a state‑run patient registry, and sets up discounted reimbursement and temporary price concessions. The bill also encourages insurers to cover these treatments and protects physicians and patients from liability and denial of access.
AI-generated summary — may be incomplete or inaccurate. Verify against the official bill text.
Ask about SB 1552
3 free questions a day, no accountHistory
- Died in Health Policy
- Introduced
- Referred to Health Policy; Appropriations Committee on Health and Human Services; Appropriations
- Filed
Sponsors
- Burgess · sponsor
Similar bills in other states
Loading the map of where bills like this one were filed.
Topics
Share
Writing about this bill? Add a live status widget to your site or newsletter. It updates as the bill moves.
Track this bill
Get an email when SB 1552 moves: committee action, floor votes, amendments and hearings. Free, no card.
Track SB 1552 freeOr ask your AI assistant about SB 1552 directly:
Add to Claude, ChatGPT or Cursor